+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Procedure and Disease Indication: Global Opportunity Analysis and Industry Forecast, 2021-2028

  • PDF Icon

    Report

  • 266 Pages
  • June 2021
  • Region: Global
  • Allied Market Research
  • ID: 5439769
Description Jump to:
The global endoscopy devices for obesity, type II diabetes and NASH market was valued at $2,638.99 million in 2019, and is projected to reach $3,711.43 million by 2027, registering a CAGR of 7.6% from 2021 to 2028. Endoscopy devices are the medical devices with light attached to look inside the body cavity or organ by inserting through a natural opening such as the mouth or through incisions. An endoscopy is the minimally invasive medical procedure that diagnoses, prevents, and treats complications associated with visceral organs. Endoscopic devices consist of flexible tubing that contains a series of lighted mirror lenses and optic fibers. These devices are used in the diagnosis of gastrointestinal tract, small intestine, large intestine/colon, bile duct, rectum, respiratory tract, ear, urinary tract, and female reproductive systems. The market mainly focuses on the endoscopic devices used in the endoscopic surgeries used in treating diseases such as obesity, type II diabetes, and non-alcoholic steatohepatitis.



Surge in obese population, technological advancements, rise in prevalence rate of diseases that require endoscopy devices, growth in patient preference for minimally invasive surgeries, favorable FDA approvals, and reimbursement policies in developed economies, shorter recovery time and minimal postoperative complications are the key factors that fuel the growth of the endoscopy devices for obesity, type II diabetes and NASH market. Furthermore, rise in prevalence of diabetes within the population is expected to supplement the market growth throughout the analysis period. For instance, according to the data published by National Institute of Health (NIH), in 2017, approximately 462 million individuals were affected by type II diabetes, corresponding to 6.28% of the world’s population. Moreover, increase in the geriatric population vulnerable to obesity and comorbid conditions related to obesity, which necessitates the use of endoscopic procedures for diagnosis & treatment is anticipated to boost the market growth in near future. However, dearth of trained physicians & endoscopists and infections associated with the use of endoscopes are expected to hinder the growth of the market.
.

The global endoscopy devices for obesity, type II diabetes and NASH market is segmented into product type, procedure, disease indication, and region. By product type, the market is categorized into endoscope, mechanical endoscopic equipment, visualization & documentation systems, accessories, and other endoscopy equipment. By procedure, the market is segmented into gastric balloon, aspiration therapy, endoscopic sleeve gastroplasty, gastric injection, and lap band surgery. On the basis of disease indication, the endoscopy devices for obesity, type II diabetes and NASH market is classified into obesity, type II diabetes and nonalcoholic steatohepatitis (NASH). Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key benefits for stakeholders

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global endoscopy devices for obesity, type II diabetes and NASH market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS


By Product

  • Endoscope
  • Mechanical endoscopic equipment
  • Visualization and documentation systems
  • Accessories
  • Other endoscopy equipment

By Procedure

  • Gastric balloon
  • Aspiration therapy
  • Endoscopic sleeve gastroplasty
  • Gastric injection
  • Lap band surgery

By Disease indication

  • Obesity
  • Type II Diabetes
  • Nonalcoholic Steatohepatitis (NASH

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Apollo Endosurgery Inc.
  • Aspire Bariatrics Inc.
  • Endo Tools Therapeutics S.A
  • Fractyl Laboratories Inc.
  • GI Dynamics Inc.
  • GI Windows Inc.
  • Medtronic plc
  • Obalon Therapeutics Inc.
  • ReShape Lifesciences Inc.
  • Spatz FGIA Inc.
  • USGI Medical Inc.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2019
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in obese population
3.5.1.2. Technological advancements
3.5.1.3. Rise in prevalence rate of diseases that require endoscopy devices
3.5.1.4. Growth in patient preference for minimally invasive surgeries
3.5.1.5. Favorable FDA approvals
3.5.1.6. Shorter recovery time and minimal postoperative complications
3.5.2. Restraints
3.5.2.1. Dearth of trained physicians and endoscopists
3.5.2.2. Infections caused by few endoscopes
3.5.3. Opportunities
3.5.3.1. Unmet medical demands in developing countries
3.5.3.2. Lucrative opportunities in emerging economies
3.6. COVID-19 impact analysis
3.7. Clinical data analysis
3.7.1. Intragastric balloons
3.7.2. AspireAssist
3.7.3. Revita DMR System
3.7.4. EndoBarrier
3.7.5. Incision-less Anastomosis System (IAS)
3.7.6. OverStitch Endoscopic Suturing System
3.7.7. Endomina
3.7.8. Plication Device
3.7.9. Endostitch
CHAPTER 4: ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Endoscopes
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Mechanical endoscopic equipment
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Visualization and documentation systems
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Accessories
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Other endoscopy equipment
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
CHAPTER 5: ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE
5.1. Overview
5.1.1. Market size and forecast
5.2. Gastric balloons
5.2.1. Key market trends and opportunities
5.2.2. Market size and forecast
5.2.3. Market analysis, by country
5.3. Aspiration therapy
5.3.1. Key trends and opportunities
5.3.2. Market size and forecast
5.3.3. Market analysis, by country
5.4. Endoscopic sleeve gastroplasty
5.4.1. Key market trends and opportunities
5.4.2. Market size and forecast
5.4.3. Market analysis, by country
5.5. Gastric injections
5.5.1. Key market trends and opportunities
5.5.2. Market size and forecast
5.5.3. Market analysis, by country
5.6. Lap band surgery
5.6.1. Key market trends and opportunities
5.6.2. Market size and forecast
5.6.3. Market analysis, by country
5.7. Others
5.7.1. Key market trends and opportunities
5.7.2. Market size and forecast
5.7.3. Market analysis, by country
CHAPTER 6: ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Obesity
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis, by country
6.3. Type II Diabetes
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis, by country
6.4. Nonalcoholic Steatohepatitis (NASH)
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis, by country
CHAPTER 7: ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by product type
7.2.4. Market size and forecast, by procedure
7.2.5. Market size and forecast, by disease indication
7.2.5.1. U.S.
7.2.5.1.1. U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.1.2. U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.1.3. U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.2.5.2. Canada
7.2.5.2.1. Canada Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.2.2. Canada Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.2.3. Canada Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.2.5.3. Mexico
7.2.5.3.1. Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.3.2. Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.3.3. Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.1.2. Germany Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.1.3. Germany Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.2. France
7.3.2.2.1. France Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.2.2. France Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.2.3. France Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.3. U. K.
7.3.2.3.1. U. K. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.3.2. U. K. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.3.3. U. K. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.4. Italy
7.3.2.4.1. Italy Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.4.2. Italy Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.4.3. Italy Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.5. Spain
7.3.2.5.1. Spain Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.5.2. Spain Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.5.3. Spain Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.6.2. Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.6.3. Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by product type
7.4.4. Market size and forecast, by procedure
7.4.5. Market size and forecast, by disease indication
7.4.5.1. China
7.4.5.1.1. China Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.1.2. China endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.1.3. China endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.2. Japan
7.4.5.2.1. Japan Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.2.2. Japan endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.2.3. Japan endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.3. India
7.4.5.3.1. India Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.3.2. India endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.3.3. India endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.4. Australia
7.4.5.4.1. Australia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.4.2. Australia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.4.3. Australia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.5.2. Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.5.3. Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by product type
7.5.4. Market size and forecast, by procedure
7.5.5. Market size and forecast, by disease indication
7.5.5.1. Brazil
7.5.5.1.1. Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.1.2. Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.1.3. Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.2. Saudi Arabia
7.5.5.2.1. Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.2.2. Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.2.3. Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.3. South Africa
7.5.5.3.1. South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.3.2. South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.3.3. South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.4.2. Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.4.3. Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
CHAPTER 8: COMPANY PROFILES
8.1. APOLLO ENDOSURGERY INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ASPIRE BARIATRICS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segment
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. ENDO TOOLS THERAPEUTICS S. A.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segment
8.3.4. Product portfolio
8.4. FRACTYL LABORATORIES INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. GI DYNAMICS INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segment
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. GI WINDOWS INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. MEDTRONIC PLC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. OBALON THERAPEUTICS INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segment
8.8.4. Product portfolio
8.8.5. Business Performance
8.9. RESHAPE LIFESCIENCES INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. SPATZ FGIA INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segment
8.10.4. Product portfolio
8.11. USGI MEDICAL INC.
8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Key strategic moves and developments
List of Tables
TABLE 01. OVERVIEW OF FDA STATUS FOR DEVICES USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 02. CLINICAL DATA OF THE GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 03. CLINICAL DATA OF THE OTHER GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 04. CLINICAL PIPELINE ANALYSIS OF GASTRIC BALLOONS
TABLE 05. CLINICAL DATA OF THE ASPIRATION THERAPY DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 06. CLINICAL PIPELINE ANALYSIS OF ASPIRATION THERAPY DEVICE
TABLE 07. CLINICAL DATA OF THE REVITA DMR SYSTEM USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 08. CLINICAL PIPELINE ANALYSIS OF REVITA DMR SYSTEM
TABLE 09. CLINICAL DATA OF ENDOBARRIER USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 10. CLINICAL PIPELINE ANALYSIS OF ENDOBARRIER
TABLE 11. CLINICAL DATA OF INCISION-LESS ANASTOMOSIS SYSTEM (IAS) USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 12. CLINICAL PIPELINE ANALYSIS OF INCISIONLESS ANASTOMOSIS
TABLE 13. CLINICAL DATA OF OVERSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 14. CLINICAL PIPELINE ANALYSIS OF OVERSTITCH ENDOSCOPIC SUTURING SYSTEM
TABLE 15. CLINICAL DATA OF ENDOMINA USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 16. CLINICAL PIPELINE ANALYSIS OF ENDOMINA
TABLE 17. CLINICAL DATA OF PLICATION DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 18. CLINICAL PIPELINE ANALYSIS OF PLICATION DEVICE
TABLE 19. CLINICAL DATA OF ENDOSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 20. CLINICAL PIPELINE ANALYSIS OF ENDOSTITCH
TABLE 21. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019–2028 ($MILLION)
TABLE 22. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY REGION, 2019–2028 ($MILLION)
TABLE 23. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY REGION, 2019–2028 ($MILLION)
TABLE 24. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEM, BY REGION, 2019–2028 ($MILLION)
TABLE 25. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY REGION, 2019–2028 ($MILLION)
TABLE 26. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY REGION, 2019–2028 ($MILLION)
TABLE 27. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019–2028 ($MILLION)
TABLE 28. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY REGION, 2019–2028 ($MILLION)
TABLE 29. ENDOSOCOPY DEVICES MARKET FOR ASPIRATION THEREAPY, BY REGION, 2019–2028 ($MILLION)
TABLE 30. ENDOSCOPIC DEVICES MARKET FOE ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2019–2028 ($MILLION)
TABLE 31. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTION, BY REGION, 2019–2028 ($MILLION)
TABLE 32. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET LAP BAND SURGERY, BY REGION, 2019–2028 ($MILLION)
TABLE 33. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET OTHERS, BY REGION, 2019–2028 ($MILLION)
TABLE 34. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION 2019-2028($MILLION)
TABLE 35. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY REGION, 2019-2028 ($MILLION)
TABLE 36. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY REGION, 2019-2028 ($MILLION)
TABLE 37. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY REGION, 2019-2028 ($MILLION)
TABLE 38. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION, 2019-2028 ($MILLION)
TABLE 39. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 40. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 41. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 42. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 43. U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028
TABLE 44. U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 45. U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 46. CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 47. CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 48. CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 49. MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 50. MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 51. MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 52. EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 53. GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 54. GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 55. GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 56. FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 57. FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 58. FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 59. U. K. ENDOSCOPY DEVICES MARKET FOR OBESITY, TYPE II DIABETES, AN BGT5D NASH, BY PRODUCT, 2019-2028
TABLE 60. U. K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 61. U. K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 62. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 63. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 64. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 65. SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 66. SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 67. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 68. REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 69. REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 70. REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 71. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 72. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 73. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 74. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 75. CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 76. CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 77. CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 78. JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 79. JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 80. JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 81. INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 82. INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 83. INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 84. AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 85. AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 86. AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 87. REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 88. REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 89. REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 90. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 91. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 92. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 93. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 94. BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 95. BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 96. BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 97. SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 98. SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 99. SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 100. SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 101. SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 102. SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 103. REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 104. REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 105. REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 106. APOLLO ENDOSURGERY: COMPANY SNAPSHOT
TABLE 107. APOLLO ENDOSURGERY: OPERATING SEGMENT
TABLE 108. APOLLO ENDOSURGERY: PRODUCT PORTFOLIO
TABLE 109. ASPIRE BARIATRICS: COMPANY SNAPSHOT
TABLE 110. ASPIRE BARIATRICS: OPERATING SEGMENT
TABLE 111. ASPIRE BARIATRICS: PRODUCT PORTFOLIO
TABLE 112. ASPIRE BARIATRICS: PRODUCT PORTFOLIO
TABLE 113. ENDO TOOLS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 114. ENDO TOOLS THERAPEUTICS: OPERATING SEGMENT
TABLE 115. ENDO TOOLS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 116. FRACTYL LABORATORIES: COMPANY SNAPSHOT
TABLE 117. FRACTYL LABORATORIES: OPERATING SEGMENTS
TABLE 118. FRACTYL LABORATORIES: PRODUCT PORTFOLIO
TABLE 119. FRACTYL LABORATORIES: PRODUCT PORTFOLIO
TABLE 120. GI DYNAMICS: COMPANY SNAPSHOT
TABLE 121. GI DYNAMICS: OPERATING SEGMENT
TABLE 122. GI DYNAMICS: PRODUCT PORTFOLIO
TABLE 123. GI DYNAMICS: PRODUCT PORTFOLIO
TABLE 124. GI WINDOWS: COMPANY SNAPSHOT
TABLE 125. GI WINDOWS: OPERATING SEGMENT
TABLE 126. GI WINDOWS: PRODUCT PORTFOLIO
TABLE 127. GI WINDOWS: PRODUCT PORTFOLIO
TABLE 128. MEDTRONIC: COMPANY SNAPSHOT
TABLE 129. MEDTRONIC: OPERATING BUSINESS SEGMENTS
TABLE 130. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 131. OBALON THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 132. OBALON THERAPEUTICS: OPERATING SEGMENT
TABLE 133. OBALON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 134. RESHAPE LIFESCIENCES: COMPANY SNAPSHOT
TABLE 135. RESHAPE LIFESCIENCES INC.: PRODUCT PORTFOLIO
TABLE 136. RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 137. SPATZ FGIA: COMPANY SNAPSHOT
TABLE 138. SPATZ FGIA: OPERATING SEGMENT
TABLE 139. SPATZ FGIA: PRODUCT PORTFOLIO
TABLE 140. USGI MEDICAL: COMPANY SNAPSHOT
TABLE 141. USGI MEDICAL: OPERATING SEGMENTS
TABLE 142. USGI MEDICAL: PRODUCT PORTFOLIO
TABLE 143. RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. GLOBAL ENDOSCOPY DEVICES MARKET: SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021*
FIGURE 01. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02. MODERATE BARGAINING POWER OF BUYERS
FIGURE 03. MODERATE THREAT OF SUBSTITUTES
FIGURE 04. MODERATE THREAT OF NEW ENTRANTS
FIGURE 05. HIGH INTENSITY OF RIVALRY
FIGURE 06. TOP PLAYER POSITIONING, 2019
FIGURE 07. DRIVERS, RESTRAINTS, OPPORTUNITIES
FIGURE 08. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEMS, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES MARKET FOR ASPIRATION THERAPY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTIONS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR LAP BAND SURGERY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 19. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY COUNTRY, 2019 & 2028
FIGURE 20. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY COUNTRY, 2019 & 2028
FIGURE 21. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY COUNTRY, 2019 & 2028
FIGURE 22. REGION WISE PREVALENCE OF DIABETES, 2019, 2030 & 2045
FIGURE 23. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 24. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 25. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 26. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 27. APOLLO ENDOSURGERY: NET SALES, 2018–2020 ($MILLION)
FIGURE 28. APOLLO ENDOSURGERY: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 29. APOLLO ENDOSURGERY: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 30. MEDTRONIC: NET SALES, 2018–2020 ($MILLION
FIGURE 31. MEDTRONIC: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 32. MEDTRONIC: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 33. OBALON THERAPEUTICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 34. RESHAPE LIFESCIENCES INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. RESHAPE LIFESCIENCES: REVENU.S.ARE BY REGION, 2020 (%)

Companies Mentioned

  • Apollo Endosurgery
  • Fractyl Laboratories
  • GI Dynamics
  • GI Windows
  • Aspire Bariatrics
  • Reshape LifeSciences Inc.
  • USGI Medical
  • Obalon Therapeutics
  • Spatz Fgia and Endo Tools Therapeutics.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Robotic Endoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Robotic Endoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) Market 2024-2028 - Product Image

Non-Alcoholic Steatohepatitis (NASH) Market 2024-2028

  • Report
  • 154 Pages
  • Global
From
Endoscopy Devices and Equipment Market Report 2024 - Product Image

Endoscopy Devices and Equipment Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Gastrointestinal (GI) Endoscopy Devices - Global Strategic Business Report - Product Image

Gastrointestinal (GI) Endoscopy Devices - Global Strategic Business Report

  • Report
  • 169 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.